Key result
PLXNA4 uniquely upregulates in cardiomyocytes of patients with end-stage ARVC.
Why the study?
The transcriptional profile of end-stage ARVC compared to other cardiomyopathies and the unique gene dysregulation in ARVC cardiomyocytes were not fully characterized.
Observational (n=19)
Yes
This study identifies PLXNA4 as a uniquely upregulated gene in ARVC cardiomyocytes that alters electrophysiology and induces immune responses, providing a potential novel molecular mechanism for the disease.
PLXNA4 merits targeted validation as an ARVC-specific cardiomyocyte mediator; leaves open its pathogenic role and therapeutic potential pending further studies.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare genetic form of heart disease often caused by mutations in desmosomal proteins. We carried out single-nucleus RNA sequencing (snRNA-seq) on 11 non-failing and 8 ARVC patient right ventricular samples and transcriptionally profiled 139,347 nuclei. We identified over 4,400 differentially expressed protein-coding genes between non-failing and ARVC samples across cell types. When compared to dilated, hypertrophic, and ischemic cardiomyopathy, we found that end-stage ARVC is transcriptionally similar to other forms of end-stage heart failure. Despite broad transcriptional similarities, we identified seven cardiomyocyte genes and six fibroblast genes that were uniquely dysregulated in ARVC and validated PLXNA4 as a gene with uniquely increased expression in cardiomyocytes in ARVC compared to other cardiomyopathies. Overexpression of PLXNA4 in hiPSC-derived ventricular cardiomyocytes induced immune response gene expression, suppressed calcium signaling, and altered cardiomyocyte electrophysiology, suggesting PLXNA4 may contribute to these pathways in ARVC.
No takes yet. Share an insight, caveat, or question.
Simonson et al. (2026) conducted an observational in Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=19). Arrhythmogenic right ventricular cardiomyopathy (ARVC) vs. Non-failing (NF) controls was evaluated on Differential gene expression in right ventricular cells. Single-nucleus RNA sequencing identified PLXNA4 as uniquely upregulated in cardiomyocytes of patients with end-stage arrhythmogenic right ventricular cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: